A case analysis of acute-on-chronic liver failure caused by abiraterone
- VernacularTitle:阿比特龙致慢加急性肝衰竭1例病例分析
- Author:
Zhun XIAO
1
;
Jinghui DAI
1
;
Weili YAO
1
;
Suping MA
1
Author Information
1. Dept. of Digestive Diseases，the First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450003，China
- Publication Type:Journal Article
- Keywords:
abiraterone;
acute-on-chronic liver failure;
adverse drug reaction;
liver failure
- From:
China Pharmacy
2023;34(14):1730-1733
- CountryChina
- Language:Chinese
-
Abstract:
Abiraterone is commonly used as a targeted drug for the treatment of prostate cancer， which commonly causes adverse drug reactions （ADR）， including abnormal liver function， fatigue， nausea and edema， etc. This study reports a 78-year-old man with a history of hepatitis B and liver cirrhosis after prostate cancer resection who was admitted to the First Affiliated Hospital of Henan University of Chinese Medicine. The patient received abiraterone treatment 1 month before admission and developed gastrointestinal symptoms 3 weeks after the treatment and worsened at 4th week with yellowing of the skin， sclera and urine. Unfortunately， the patient died after 5 weeks of abiraterone treatment （1 week after admission）. Based on test and examination results， the patient was diagnosed with acute-on-chronic liver failure （ACLF）. This paper analyzes the patient’s medical history and the relevant treatment in detail. It is evaluated that ACLF and abiraterone are “probably” related based on Naranjo ADR Probability Scale， suggesting abiraterone may induce severe ADR of liver failure in patients with chronic liver diseases such as cirrhosis. These patients should be monitored dynamically for changes in liver function and treated prophylactically with liver-protective drugs if necessary.
